查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1931231

髖關節疼痛治療解決方案市場（按治療類型、年齡層、最終用戶和分銷管道分類），全球預測（2026-2032年）

Hip Pain Therapy Solutions Market by Therapy Type, Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年髖關節疼痛治療解決方案市值為 4.2731 億美元，預計到 2026 年將成長至 4.4528 億美元，複合年成長率為 5.21%，到 2032 年將達到 6.0994 億美元。

關鍵市場統計數據
基準年 2025 4.2731億美元
預計年份：2026年 4.4528億美元
預測年份 2032 6.0994億美元
複合年成長率 (%) 5.21%

本文全面介紹了現代醫學中髖關節疼痛治療方案的臨床複雜性、相關人員趨勢和策略重點。

髖關節疼痛反映了臨床複雜性、患者期望和不斷發展的治療方法三者交匯融合的特徵。近年來，治療途徑已從保守治療擴展到先進的外科手術和再生醫學干預，而支付方和醫療服務提供者也在修訂准入、報銷和臨床通訊協定，以平衡療效和成本。人口結構變化、活動模式改變和技術進步之間的相互作用，凸顯了整合觀點的重要性，該視角應涵蓋治療方法類型、醫療機構和通路。

本文詳細說明了正在重塑髖關節疼痛治療方案和護理服務的主要臨床、技術和報銷主導所帶來的變革。

臨床創新、不斷變化的醫療保健模式以及患者期望的轉變，共同重塑了髖關節疼痛的評估和治療方式。影像技術和診斷演算法的進步，使得關節和軟組織病變的識別更加早期、精準，從而支持早期療育策略和個人化治療方案的選擇。同時，微創手術技術和關節鏡技術的改進，也改變了手術全期流程，使部分患者能夠縮短住院時間，並加快功能恢復。

檢驗2025年價格調整對美國髖關節疼痛治療相關人員的供應鏈韌性、籌資策略和臨床經濟學的影響。

近期政策週期中實施的關稅調整對醫療設備和藥品供應鏈產生了顯著的連鎖反應，影響了膝關節疼痛治療的採購、定價和臨床規劃。外科植入、器械和某些生物製劑處理試劑盒的組件通常來自全球供應商。進口關稅的提高將推高到岸成本，並可能迫使供應商重新評估其籌資策略。事實上，這種壓力已促使一些供應鏈管理者延長合約期限、拓展供應商範圍，或盡可能轉向國內採購，以穩定採購並保障利潤。

全面的細分分析揭示了治療方法類型、醫療保健環境、通路和年齡層如何共同塑造臨床需求和採納路徑。

治療方法方案的選擇取決於臨床症狀和患者目標。保守治療優先考慮輔助器具、結構化物理治療和體重管理，以延緩侵入性手術並改善功能。藥物治療著重於針對性症狀管理，包括使用皮質類固醇治療局部炎症，使用非類固醇抗發炎藥物緩解全身疼痛，以及在嚴格遵循通訊協定的前提下，謹慎使用鴉片類藥物治療急性重度疼痛。再生醫學療法（例如富血小板血漿療法和幹細胞療法）是一個新興領域，患者和臨床醫生都在尋求生物學解決方案來促進癒合。手術方案根據其侵入性和適應症進行分類，髖關節鏡手術適用於局部關節內問題，微創技術可減輕術後恢復負擔，而全髖置換術則用於治療進行性退化性疾病或大規模的結構性損傷。

分析區域差異，重點介紹美洲、歐洲、中東和非洲以及亞太地區在報銷制度、醫療服務基礎設施和採用模式方面的差異。

在美洲，醫療報銷模式多元，私部門正積極採用創新技術。整形外科診所和門診手術中心之間密切合作，微創手術和快速復健計畫備受重視。支付方談判的趨勢影響著醫療設備的選擇和綜合報銷方案的設計，而遍遠地區的醫療資源匱乏和專科醫生分佈的區域差異則影響著轉診模式，因此需要利用遠端醫療手段，開展有針對性的推廣和後續隨訪，以彌合醫療保健方面的差距。

實用的企業資料，檢驗證據生成、供應靈活性和綜合臨床支援如何推動解決方案供應商之間的競爭情報。

領先的製造商和服務供應商透過臨床證據、整合式服務交付和靈活的商業模式來脫穎而出。那些優先考慮強力的臨床計畫（包括投資於比較療效研究、真實世界結果追蹤和系統性的上市後監測）的公司，往往能獲得醫療機構更高的採納率和支付方的認可。當證據顯示微創和再生醫學解決方案能夠改善功能性結果並帶來特定手術益處時，與臨床領導者和專家中心建立合作關係能夠加速這些解決方案的早期應用。

為產業領導者提供策略建議，以整合證據產生、供應鏈韌性和商業化策略，從而實現持續應用和影響力。

優先考慮符合支付方價值標準和對患者及醫療系統至關重要的臨床終點的證據。投資前瞻性註冊研究和真實世界證據，以量化功能改善、再入院率降低和總醫療成本。同時，開發靈活的合約模式，以反映全面的診療路徑並提供可預測的定價，從而便於支付方評估。加強臨床、市場進入和商業團隊之間的跨職能協作，以加速與支付方的對話並支援將醫療服務整合到診療路徑中。

一項解釋透明的研究設計，結合了多種調查方法（文獻綜述、相關人員訪談和比較路徑檢驗），以確保研究結果的可靠性。

本分析系統地回顧了同行評審的臨床文獻、監管指南和已發布的政策文件，以繪製髖關節疼痛的治療路徑和臨床結果圖譜。除了文獻綜述外，還對臨床醫生、醫院採購人員和配送專業人員進行定性相關人員調查，檢驗僅憑文獻無法揭示的實際挑戰和營運限制。這些相關人員訪談有助於對不同醫療機構的實際實踐模式和實施障礙進行三角驗證。

簡潔扼要的結論重點闡述了成功實施髖關節疼痛治療並實現其價值交付的策略重點和營運槓桿。

髖關節疼痛的治療越來越取決於臨床創新、以價值主導的報銷機制和營運執行之間的相互作用。隨著保守治療、藥物治療、再生療法和手術治療方案的逐步成熟，關鍵的差異化因素將在於相關人員如何將臨床證據轉化為可及且經濟有效的治療途徑。能夠將嚴謹的療效數據與切實可行的服務模式和供應鏈韌性相結合的醫療服務提供者和製造商，將在醫療系統和支付方中贏得優先地位。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按治療方法的髖關節疼痛治療解決方案市場

  • 保守治療
    • 輔助器具
    • 物理治療
    • 體重管理
  • 藥物治療
    • 皮質類固醇
    • 非類固醇消炎劑（NSAIDs）
    • 鴉片類藥物
  • 再生醫學
    • 富血小板血漿
    • 幹細胞療法
  • 外科
    • 髖關節鏡檢查
    • 微創
    • 全髖關節置換術

9. 依年齡層分類的髖關節疼痛治療方案市場

  • 成人版
  • 老年人
  • 兒童

第10章 按最終使用者分類的髖關節疼痛治療解決方案市場

  • 門診治療中心
  • 居家醫療
  • 醫院
  • 整形外科診所

第11章 按分銷管道分類的髖關節疼痛治療解決方案市場

  • 線上
  • 離線

12. 按地區分類的髖關節疼痛治療解決方案市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 按群體分類的髖關節疼痛治療解決方案市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國髖關節疼痛治療計畫市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國髖關節疼痛治療計畫市場

第16章：中國髖關節疼痛治療方案市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alkem Laboratories Ltd.
  • Anika Therapeutics, Inc.
  • B. Braun Melsungen AG
  • Bioventus Inc.
  • Cipla Ltd.
  • DJO Global, Inc.
  • Fix Health（YourPhysio Pvt. Ltd.）
  • Healyos Pvt. Ltd.
  • Jiva Ayurveda Clinic Pvt. Ltd.
  • Johnson & Johnson
  • Medtronic plc
  • Meril Life Sciences Pvt. Ltd.
  • Ortho Sport & Spine Physicians, LLC
  • Penn Medicine
  • Pfizer Inc.
  • RegenOrthoSport Pvt. Ltd.
  • Smith & Nephew plc
  • Stryker Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-7B550E008DD3

The Hip Pain Therapy Solutions Market was valued at USD 427.31 million in 2025 and is projected to grow to USD 445.28 million in 2026, with a CAGR of 5.21%, reaching USD 609.94 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 427.31 million
Estimated Year [2026] USD 445.28 million
Forecast Year [2032] USD 609.94 million
CAGR (%) 5.21%

Comprehensive introduction outlining the clinical complexity, stakeholder dynamics, and strategic priorities framing hip pain therapy solutions in contemporary care

Hip pain represents a convergence of clinical complexity, patient expectations, and evolving therapeutic modalities. In recent years, care pathways have diversified from conservative management through to advanced surgical and regenerative interventions, while payers and providers have recalibrated access, reimbursement, and clinical protocols to balance outcomes and costs. The interplay of demographic shifts, activity patterns, and technological advances has elevated the importance of an integrated view that spans therapy type, care setting, and distribution channel.

This executive summary synthesizes key patterns shaping the sector, spotlighting clinical innovation, supply chain dynamics, payer influences, and regional contrasts. It frames actionable principles for industry leaders, clinical program managers, and policy planners who must translate emerging evidence into operational plans. The narrative emphasizes practical implications rather than granular estimates, providing a foundation to prioritize investments, refine stakeholder engagement, and accelerate adoption of clinically validated approaches.

By focusing on the mechanisms driving demand, adoption, and competitive differentiation, readers will gain a compact, strategically oriented perspective. The content that follows bridges clinical realities with market-facing levers, enabling readers to identify immediate risks and near-term opportunities while preparing for longer-term shifts in therapy delivery and patient expectations.

Detailed exposition of the major clinical, technological, and reimbursement-driven transformations reshaping hip pain therapy selection and care delivery

Clinical innovation, shifting reimbursement models, and evolving patient expectations have collectively redefined how hip pain is evaluated and treated. Advances in imaging and diagnostic algorithms enable earlier, more precise identification of joint and soft tissue pathology, which in turn supports earlier intervention strategies and tailored therapy selection. At the same time, minimally invasive surgical techniques and refinements in arthroscopy have altered perioperative pathways, reducing length of stay and accelerating functional recovery for selected patients.

Concurrently, nonoperative options are expanding beyond traditional analgesia and physical therapy to include targeted regenerative interventions and integrated care models that emphasize multidisciplinary rehabilitation and long-term function. Health systems and orthopedic providers increasingly align care bundles with value metrics, tying pathway adherence to outcome-based reimbursement and patient-reported measures. As a result, commercial and clinical stakeholders must adapt product positioning, evidence generation, and value communication to meet tighter scrutiny from payers and institutions.

Technology and data are accelerating these trends. Digital therapeutics, remote monitoring, and tele-rehabilitation increasingly complement in-person care, enabling longitudinal management and better adherence tracking. As these forces interact, the market is shifting toward evidence-driven, patient-centric models that privilege demonstrable functional improvement and cost-effective care delivery.

Examination of how 2025 tariff adjustments reshaped supply resilience, procurement strategies, and clinical economics for hip pain therapy stakeholders in the United States

Tariff adjustments enacted in recent policy cycles have created material ripple effects across medical device and pharmaceutical supply chains, which in turn influence procurement, pricing, and clinical planning for hip pain therapies. Components used in surgical implants, instruments, and certain biologic processing kits often originate from global suppliers; increased import duties can raise landed costs and compel providers to reassess sourcing strategies. In practice, this pressure has led some supply managers to shift toward longer contract terms, diversify vendor lists, or source domestically where feasible to stabilize procurement and protect margin.

Beyond direct cost implications, tariffs can prompt manufacturers to revisit supply chain footprints and operational footprints, accelerating moves to localize critical manufacturing steps or nearshore selected operations to mitigate future policy volatility. These strategic responses have secondary effects on capital expenditure and product lead times, sometimes lengthening the interval between order and delivery and complicating inventory planning in hospitals and ambulatory centers.

Clinicians and health system leaders respond to these dynamics by enhancing cross-functional planning between clinical, procurement, and finance teams. In turn, commercial organizations that offer flexible contract structures, localized inventory support, or bundled service offerings find it easier to maintain adoption momentum. Ultimately, tariffs represent a macro-level risk that reshuffles cost bases and supply relationships, incentivizing resilience, transparency, and tighter coordination across the ecosystem.

Comprehensive segmentation insights revealing how therapy modalities, care settings, distribution channels, and age cohorts collectively shape clinical demand and adoption pathways

Therapy selection reflects clinical presentation and patient goals, with conservative approaches prioritizing assistive devices, structured physical therapy, and weight management to delay invasive interventions and improve function. Pharmacologic strategies emphasize targeted symptom control via corticosteroids for localized inflammation, NSAIDs for broad analgesic needs, and cautious opioid use reserved for acute, severe pain under strict protocols. Regenerative options, including platelet-rich plasma and stem cell therapies, occupy a growing niche where patients and clinicians seek biologically oriented solutions to augment healing. Surgical pathways subdivide by invasiveness and indication, with hip arthroscopy applied to focal intra-articular problems, minimally invasive techniques reducing recovery burdens, and total hip replacement reserved for advanced degenerative disease and large-scale structural compromise.

Care delivery settings shape access, throughput, and the patient experience. Ambulatory care centers-whether hospital-affiliated or standalone-offer focused procedural throughput and shorter stays, while home care models, spanning professional home nursing to self-managed rehabilitation, extend recovery into the patient's environment and can reduce readmission risk. Hospitals, including general institutions, specialty orthopedic centers, and teaching hospitals, provide the full spectrum of acute and complex care, and orthopedic clinics, whether group or private practices, often serve as the primary referral and follow-up hub.

The distribution landscape influences availability and channel economics. Hospital pharmacies, split between inpatient and outpatient services, manage immediate perioperative and discharge medication needs. Online pharmacies, through direct-to-patient offerings or third-party platforms, expand convenience for chronic pharmacologic regimens. Retail pharmacies, both chain and independent, remain essential for community access and adherence. Age stratification also matters: adults aged 18-64 experience different activity-related etiologies than geriatric cohorts aged 65 and above, who present with degenerative patterns and distinct comorbidity profiles, while pediatric patients require tailored diagnostic and therapeutic approaches reflecting growth and development considerations.

Nuanced regional analysis highlighting how reimbursement, provider infrastructure, and adoption patterns vary across the Americas, Europe Middle East and Africa, and Asia Pacific

The Americas display heterogeneous reimbursement models and robust private-sector innovation adoption, with strong integration between orthopedics practices and ambulatory procedural centers that favor minimally invasive surgery and rapid recovery programs. Payer negotiation dynamics influence device selection and bundle design, while regional disparities in rural access and specialist distribution shape referral patterns, prompting targeted outreach and telehealth-enabled follow-up models to bridge care gaps.

Europe, the Middle East & Africa exhibits a complex mosaic of public and private financing, with many health systems emphasizing cost-effectiveness and standardized care pathways. Regulatory scrutiny and centralized procurement mechanisms often lead to longer adoption cycles for novel devices and biologics, yet there is persistent interest in interventions that demonstrably reduce hospital stay and long-term disability. Variability across jurisdictions necessitates localized evidence generation and payer dialogue to secure pathway inclusion.

Asia-Pacific combines rapid capacity expansion, increasing surgical throughput, and a rising emphasis on regenerative medicine and biologics. Many markets are modernizing infrastructure, accelerating adoption of outpatient surgery models and leveraging private investment to enhance orthopedic service lines. However, heterogeneity in reimbursement and private-public mix requires tailored commercialization strategies that account for local clinical practices, price sensitivity, and distribution logistics.

Actionable corporate intelligence examining how evidence generation, supply agility, and integrated clinical support drive competitive leadership among solution providers

Leading manufacturers and service providers differentiate through clinical evidence, integrated service offerings, and flexible commercial models. Those that prioritize robust clinical programs-investing in comparative effectiveness studies, real-world outcome tracking, and structured post-market surveillance-tend to secure stronger institutional adoption and payer recognition. Partnerships with clinician leaders and specialty centers accelerate early adoption of minimally invasive and regenerative solutions when evidence demonstrates improved functional outcomes and procedure-specific benefits.

Competitive advantage also emerges from supply chain agility and service models that reduce friction for health systems. Companies that support bundled procurement, provide local inventory management, or offer clinical training and pathway integration services reduce adoption barriers. Additionally, those developing digital adjuncts-tele-rehabilitation platforms, remote monitoring solutions, and patient engagement tools-enhance long-term adherence and capture outcomes data that strengthen the value proposition.

Strategic mergers, targeted acquisitions, and alliances with distributors or specialized clinics further expand geographic reach and expedite entry into constrained reimbursement environments. Ultimately, firms that balance rigorous evidence programs with pragmatic commercial support and outcome-focused partnerships position themselves to lead in a market where institutional decision-making increasingly emphasizes total cost of care and demonstrable functional benefit.

Strategically focused recommendations to help industry leaders align evidence generation, supply resiliency, and commercialization tactics for sustained adoption and impact

Prioritize evidence that aligns with payer value criteria and clinical endpoints that matter to patients and systems; invest in prospective registries and real-world evidence that quantify functional improvement, reduced readmission, and total cost of care. Simultaneously, develop flexible contracting models that reflect bundled care pathways and offer predictable pricing that eases payer evaluation. Strengthen cross-functional engagement between clinical affairs, market access, and commercial teams to accelerate payer dialogues and support inclusion in care pathways.

Enhance supply chain resilience by diversifying supplier bases, nearshoring critical components where possible, and offering localized inventory support to mitigate tariff-driven and geopolitical risks. Build clinical training and pathway-integration programs that reduce friction for adoption and demonstrate measurable improvements in perioperative efficiency and patient satisfaction. Leverage digital adjuncts-remote monitoring, tele-rehabilitation, and patient engagement platforms-to extend care beyond the clinic and capture longitudinal outcomes that reinforce the therapy's value proposition.

Finally, adopt a region-specific approach to commercialization, tailoring evidence packages, pricing frameworks, and distribution partnerships to local reimbursement realities and provider infrastructures. By combining rigorous evidence generation with operational flexibility and a patient-centered narrative, industry leaders can achieve sustained adoption and meaningful clinical impact.

Transparent explanation of the mixed-methods research design combining literature synthesis, stakeholder interviews, and comparative pathway validation to ensure robust insights

This analysis integrates a structured review of peer-reviewed clinical literature, regulatory guidance, and publicly available policy documents to map therapeutic pathways and clinical outcomes relevant to hip pain. The approach pairs literature synthesis with qualitative stakeholder engagement across clinicians, hospital procurement leaders, and distribution specialists to validate practical implications and to surface operational constraints that literature alone may not reveal. These stakeholder interviews support triangulation of real-world practice patterns and adoption barriers across different care settings.

Comparative pathway analysis evaluates how clinical decision trees vary by presentation, comorbidity, and patient age, and considers how distribution and end-user dynamics shape access. The methodology also examines payer mechanisms and procurement frameworks to understand reimbursement hurdles and adoption timelines. Wherever possible, evidence is contextualized with case examples of care model redesigns and implementation lessons that inform recommendations.

Throughout, the research prioritizes transparency in data sources and analytical assumptions, ensuring that conclusions reflect convergent signals from multiple inputs rather than single-study inferences. This mixed-methods approach yields practical insights for clinical, commercial, and policy stakeholders seeking to align strategy with evolving care realities.

Concise conclusion distilling the strategic priorities and operational levers that will define successful hip pain therapy adoption and value delivery

Hip pain therapy is increasingly defined by the interplay of clinical innovation, value-driven reimbursement, and operational execution. As conservative, pharmacologic, regenerative, and surgical options mature in parallel, the decisive differentiator will be how stakeholders translate clinical evidence into accessible, cost-effective care pathways. Providers and manufacturers that align rigorous outcomes data with pragmatic service models and supply chain resilience will secure preferential positioning with health systems and payers.

Immediate priorities include strengthening evidence generation that speaks to functional outcomes and long-term recovery, optimizing channel and site-of-care strategies to match patient needs and payer expectations, and implementing procurement and partnership models that mitigate policy and tariff-related uncertainties. By focusing on these levers, organizations can both improve patient experiences and create defensible commercial advantages.

Looking ahead, the sector will continue to evolve around integrated care models and digital enhancements that support continuous monitoring and rehabilitation. Stakeholders who proactively invest in these areas will be best placed to capture value while improving clinical outcomes and operational efficiency across diverse care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hip Pain Therapy Solutions Market, by Therapy Type

  • 8.1. Conservative
    • 8.1.1. Assistive Devices
    • 8.1.2. Physical Therapy
    • 8.1.3. Weight Management
  • 8.2. Pharmacologic
    • 8.2.1. Corticosteroids
    • 8.2.2. NSAIDs
    • 8.2.3. Opioids
  • 8.3. Regenerative
    • 8.3.1. Platelet-Rich Plasma
    • 8.3.2. Stem Cell Therapy
  • 8.4. Surgical
    • 8.4.1. Hip Arthroscopy
    • 8.4.2. Minimally Invasive
    • 8.4.3. Total Hip Replacement

9. Hip Pain Therapy Solutions Market, by Age Group

  • 9.1. Adult
  • 9.2. Geriatric
  • 9.3. Pediatric

10. Hip Pain Therapy Solutions Market, by End User

  • 10.1. Ambulatory Care Centers
  • 10.2. Home Care
  • 10.3. Hospitals
  • 10.4. Orthopedic Clinics

11. Hip Pain Therapy Solutions Market, by Distribution Channel

  • 11.1. Online
  • 11.2. Offline

12. Hip Pain Therapy Solutions Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Hip Pain Therapy Solutions Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Hip Pain Therapy Solutions Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Hip Pain Therapy Solutions Market

16. China Hip Pain Therapy Solutions Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Alkem Laboratories Ltd.
  • 17.6. Anika Therapeutics, Inc.
  • 17.7. B. Braun Melsungen AG
  • 17.8. Bioventus Inc.
  • 17.9. Cipla Ltd.
  • 17.10. DJO Global, Inc.
  • 17.11. Fix Health (YourPhysio Pvt. Ltd.)
  • 17.12. Healyos Pvt. Ltd.
  • 17.13. Jiva Ayurveda Clinic Pvt. Ltd.
  • 17.14. Johnson & Johnson
  • 17.15. Medtronic plc
  • 17.16. Meril Life Sciences Pvt. Ltd.
  • 17.17. Ortho Sport & Spine Physicians, LLC
  • 17.18. Penn Medicine
  • 17.19. Pfizer Inc.
  • 17.20. RegenOrthoSport Pvt. Ltd.
  • 17.21. Smith & Nephew plc
  • 17.22. Stryker Corporation
  • 17.23. Teva Pharmaceutical Industries Ltd.
  • 17.24. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HIP PAIN THERAPY SOLUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY ASSISTIVE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY ASSISTIVE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY ASSISTIVE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY WEIGHT MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY WEIGHT MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY WEIGHT MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY HIP ARTHROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY HIP ARTHROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY HIP ARTHROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY TOTAL HIP REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY TOTAL HIP REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY TOTAL HIP REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY ORTHOPEDIC CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY ORTHOPEDIC CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY ORTHOPEDIC CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. GCC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. GCC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
  • TABLE 168. GCC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 169. GCC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
  • TABLE 170. GCC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 171. GCC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GCC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. GCC HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. G7 HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. G7 HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
  • TABLE 195. G7 HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 196. G7 HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
  • TABLE 197. G7 HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 198. G7 HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. G7 HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. G7 HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. NATO HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. NATO HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
  • TABLE 204. NATO HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 205. NATO HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
  • TABLE 206. NATO HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 207. NATO HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. NATO HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. NATO HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES HIP PAIN THERAPY SOLUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY CONSERVATIVE, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY PHARMACOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY REGENERATIVE, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA HIP PAIN THERAPY SOLUTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)